Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation
- PMID: 18496372
- DOI: 10.1097/CCM.0b013e318174d499
Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation
Abstract
Objectives: To estimate the efficacy and metabolic effects of growth hormone substitution as intravenous pulses together with alanyl-glutamine supplementation and tight blood glucose control in prolonged critical illness.
Design: Prospective double-blind, randomized trial with open-label control arm.
Setting: Intensive care unit of tertiary level hospital.
Patients: Thirty multiple trauma patients (median Injury Severity Score 34).
Interventions: Patients were randomized, at day 4 after trauma, to receive intravenous alanyl-glutamine supplementation (0.3 g/kg x day(-1) from day 4 until day 17) and intravenous growth hormone (administered days 7-17, full dose 50 microg/kg x day(-1) from day 10 onward) (group 1, n = 10) or alanyl-glutamine and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous nutrition (proteins 1.5 g/kg x day(-1)) without alanyl-glutamine.
Measurements and main results: Cumulative nitrogen balance for the whole study period was -97 +/- 38 g of nitrogen for group 1, -193 +/- 50 g of nitrogen for group 2, and -198 +/- 77 g of nitrogen for group 3 (p < .001). This represents a daily saving of 300 g of lean body mass in group 1. Insulin-mediated glucose disposal, during euglycemic clamp, as a measure of insulin sensitivity, significantly worsened between days 4 and 17 in group 1 but improved in groups 2 and 3. Group 1 required significantly more insulin to control blood glucose, resulting in higher insulinemia (approximately 70 mIU in group 1 vs. approximately 25 mIU in groups 2 and 3). Despite this, growth hormone treatment caused an increase in plasma nonesterified fatty acid (approximately 0.5-0.6 mM in group 1 in comparison with approximately 0.2-0.3 mM in groups 2 and 3) but did not influence lipid oxidation. There were no differences in morbidity, mortality, or 6-month outcome among the groups.
Conclusions: Treatment with frequent intravenous pulses of low-dose growth hormone together with alanyl-glutamine supplementation improves nitrogen economy in patients with prolonged critical illness after multiple trauma but worsens insulin sensitivity. Tight blood glucose control is possible but requires higher doses of insulin.
Comment in
-
Growth hormone to catabolic patients revisited.Crit Care Med. 2008 Jun;36(6):1952-3. doi: 10.1097/CCM.0b013e318176aa4a. Crit Care Med. 2008. PMID: 18520646 No abstract available.
Similar articles
-
Frequent intravenous pulses of growth hormone together with alanylglutamine supplementation in prolonged critical illness after multiple trauma: effects on glucose control, plasma IGF-I and glutamine.Growth Horm IGF Res. 2008 Feb;18(1):82-7. doi: 10.1016/j.ghir.2007.07.003. Epub 2007 Aug 20. Growth Horm IGF Res. 2008. PMID: 17709266 Clinical Trial.
-
Parenterally administered dipeptide alanyl-glutamine prevents worsening of insulin sensitivity in multiple-trauma patients.Crit Care Med. 2006 Feb;34(2):381-6. doi: 10.1097/01.ccm.0000196829.30741.d4. Crit Care Med. 2006. PMID: 16424718 Clinical Trial.
-
L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study.Crit Care Med. 2006 Mar;34(3):598-604. doi: 10.1097/01.CCM.0000201004.30750.D1. Crit Care Med. 2006. PMID: 16505644 Clinical Trial.
-
[Administration of glutamine and its dipeptides in parenteral nutrition. Which patients are candidates?].Nutr Hosp. 1998 Jan-Feb;13(1):8-20. Nutr Hosp. 1998. PMID: 9578682 Review. Spanish.
-
When Is It Appropriate to Use Glutamine in Critical Illness?Nutr Clin Pract. 2016 Aug;31(4):445-50. doi: 10.1177/0884533616651318. Epub 2016 May 31. Nutr Clin Pract. 2016. PMID: 27246308 Review.
Cited by
-
Parenteral glutamine supplementation in critical illness: a systematic review.Crit Care. 2014 Apr 18;18(2):R76. doi: 10.1186/cc13836. Crit Care. 2014. PMID: 24745648 Free PMC article.
-
Glutamine Supplementation in Intensive Care Patients: A Meta-Analysis of Randomized Clinical Trials.Medicine (Baltimore). 2015 Aug;94(31):e1319. doi: 10.1097/MD.0000000000001319. Medicine (Baltimore). 2015. PMID: 26252319 Free PMC article.
-
The Effect of Amino Acids on Wound Healing: A Systematic Review and Meta-Analysis on Arginine and Glutamine.Nutrients. 2021 Jul 22;13(8):2498. doi: 10.3390/nu13082498. Nutrients. 2021. PMID: 34444657 Free PMC article.
-
Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness.Crit Care. 2015 Dec 24;19:448. doi: 10.1186/s13054-015-1160-x. Crit Care. 2015. PMID: 26699134 Free PMC article.
-
Effects of growth hormone and insulin-like growth factor-1 on postoperative muscle and substrate metabolism.J Nutr Metab. 2010;2010:647929. doi: 10.1155/2010/647929. Epub 2009 Nov 22. J Nutr Metab. 2010. PMID: 20798757 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical